| Li, Xiaosong |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
| Bian, Jiaming |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
| Xue, Sheng |
REACH, NCT05010525: A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors |
|
|
| Terminated | 1/2 | 8 | RoW | ATG-016 | Shanghai Antengene Corporation Limited | Advanced Solid Tumors | 11/22 | 11/22 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
